Clinical trials: Oral Phase
Cocaine Dependency
A Safety, Tolerability and Pharmacokinetic Study of CPP-115
Primary Objective: To evaluate the safety and tolerability of ascending single oral doses of CPP-115 Secondary Objective: To determine the pharmacokinetic profiles of CPP-115 following administration of a ascending single oral…
- Trial name
- NCT01493596
- Testing
- CPP-115
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Hepatic Impairment, Healthy Volunteers
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
The purpose of this study is to characterize the single-dose plasma PK of mobocertinib and its active metabolites (AP32960 and AP32914) in participants with moderate and/or severe HI compared to matched-healthy participants with…
- Trial name
- NCT04056468
- Testing
- Mobocertinib
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy Volunteers
A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet
The purposes of this study are to evaluate BE between a single-dose of TAK-438ASA tablet versus a single-dose combination of TAK-438 tablet 10 milligram (mg) and aspirin enteric-coated tablet 100 mg in Japanese healthy adult men…
- Trial name
- NCT03456960
- Testing
- TAK-438ASA, TAK-438, Aspirin
- Where
- Japan
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Takeda
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Advanced Solid Malignancies, Hematologic Malignancies
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.
- Trial name
- NCT01351350
- Testing
- MLN0128, paclitaxel, trastuzumab
- Where
- 3 sites in United States
- Volunteers
- 68 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Sarcoma, Oral Mucositis
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
Primary: 1. To evaluate the preliminary efficacy of palifermin in reducing the incidence and severity of oral mucositis (OM) in patients with sarcoma receiving multicycle chemotherapy. 2.
- Trial name
- NCT00267046
- Testing
- Palifermin, Adriamycin (Doxorubicin), Ifosfamide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
The purpose of this study is to determine the effectiveness and side effects of a new combination and schedule of chemotherapy drugs in the treatment of head and neck cancer.
- Trial name
- NCT00148122
- Testing
- Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Dysphagia, Pain
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer
This randomized pilot clinical trial studies dexamethasone in reducing oral pain and dry mouth after surgery in patients with oropharyngeal cancer. Dexamethasone may help lower pain and dry mouth caused by surgery.
- Conditions
- Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT01748942
- Testing
- Dexamethasone, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- OHSU Knight Cancer Institute
Abuse Potential
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational…
- Trial name
- NCT05319756
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Healthy Volunteers
Phase 1, TAK-648, Single-Rising Dose Study
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of TAK-648 when administered as a single oral dose of TAK-648 solution at escalating dose levels in healthy participants.
- Trial name
- NCT02684396
- Testing
- TAK-648
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Takeda
Allergic Bronchopulmonary Aspergillosis
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
The primary safety objectives were: Part 1: To determine the safety and tolerability of single doses of ZP-059 in healthy subjects Part 2: To determine the safety and tolerability of multiple doses of ZP-059 in subjects with mild…
- Trial name
- NCT04229303
- Testing
- Voriconazole inhaled, oral voriconazole
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Malaria
Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets
This is a single-centre, 2-part, randomised, single-dose parallel group study in healthy male subjects and female subjects of non-childbearing potential.
- Trial name
- NCT02387580
- Testing
- OZ439 + TPGS, OZ439 Prototype 1, OZ439 Prototype 3
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Classical Hodgkin's Lymphoma
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant.
- Trial name
- NCT00742027
- Testing
- Panobinostat
- Where
- 46 sites in United States, Australia and 11 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Neoplasms
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
Since the mortality rates for patients with advanced ovarian carinoma are high, the most likely way to improve progression free and overall survival is with maximal "upfront" therapy (Morrow \& Curtin, 1998).
- Trial name
- NCT00976183
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gynecologic Oncology Associates
Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called pexidartinib for the treatment of certain tumors for which surgical removal could cause more harm than good.
- Conditions
- Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
- Trial name
- ENLIVEN (NCT02371369)
- Testing
- Pexidartinib
- Where
- 39 sites in United States, Australia and 10 more
- Volunteers
- 120 people
- Sponsor
- Daiichi Sankyo
Salivary Gland Cancer
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.
- Trial name
- NCT03172624
- Testing
- Nivolumab, Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy
The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) monotherapy in patients with PNH that are treatment naïve, or patients currently treated with eculizumab who still…
- Trial name
- NCT04170023
- Testing
- ALXN2050
- Where
- 11 sites in Canada, Italy and 5 more
- Volunteers
- 29 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Head and Neck Cancer, Mucositis Oral
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy.
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Trial name
- NCT00293462
- Testing
- sargramostim, oral salt and soda mouthwash
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Marilyn Dodd
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy).
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ
- Trial name
- NCT02314156
- Testing
- Telapristone Acetate, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Northwestern University
Ependymoma
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in…
- Trial name
- NCT01247922
- Testing
- Erlotinib
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 4 people
- Sponsor
- OSI Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.